Mgr. Eva ŘEZNÍČKOVÁ, Ph.D.

Avatar
Contact

585634854

Katedra experimentální biologie

Přírodovědecká fakulta

Šlechtitelů 27 A (hlavní budova)

3.23

věd. prac. ob. biologických

ČLÁNEK
Varvuolytė G., Řezníčková E., Bieliauskas A., Vojáčková V., .., Žukauskaite A., Kryštof V. Synthesis and photodynamic activity of new 5-[(E)-2-(3-alkoxy-1-phenyl-1H-pyrazol-4-yl)ethenyl]-2-phenyl-3H-indoles. ARCHIV DER PHARMAZIE. 2024.
Dostálová H., Jorda R., Řezníčková E., Kryštof V. Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. INVESTIGATIONAL NEW DRUGS. 2023.
Ganai AM., Pathan TK., Mohite SB., Vojáčková V., Řezníčková E., Kozlanská K., Kryštof V. Design and synthesis of novel 1,2,4-triazolo[4,3-b]pyridazine derivatives with anti-cancer activity. JOURNAL OF MOLECULAR STRUCTURE. 2023.
Kovalová M., Havlíček L., Djukic S., Peřina M., Pospíšil T., Řezníčková E., Jorda R., Kryštof V. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7. BIOMEDICINE & PHARMACOTHERAPY. 2023.
Břehová P., Řezníčková E., Škach K., Jorda R., Vojáčková V., Kovalová M., Kinnertová M., Gucký T., Kryštof V. Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping. JOURNAL OF MEDICINAL CHEMISTRY. 2023.
Vlková K., Padrtová R., Gucký T., Peřina M., Řezníčková E., Kryštof V. Synthesis and biological activity evaluation of novel 3,5,7-trisubstituted pyrazolo[1,5-a]pyrimidines. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2023.
Porubský M., Řezníčková E., Křupková S., Kryštof V., Hlaváč J. Development of fluorescent dual-FRET probe for simultaneous detection of caspase-8 and caspase-9 activities and their relative quantification. BIOORGANIC CHEMISTRY. 2022.
Řezníčková E., Krajčovičová S., Peřina M., Kovalová M., Soural M., Kryštof V. Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC). EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2022.
Vlková K., Gucký T., Peřina M., Řezníčková E., Kryštof V. Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2022.
Tomanová M., Kozlanská K., Jorda R., Jedinák L., Havlíková T., Řezníčková E., Peřina M., Klener P., Dolníková A., Cankař P., Kryštof V. Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022.
Razmienė B., Vojáčková V., Řezníčková E., Malina L., Kubala M., Bajgar R., Kolářová H., Žukauskaite A., Kryštof V. Synthesis of N-aryl-2,6-diphenyl-2H-pyrazolo[4,3-c]pyridin-7-amines and their photodynamic properties in the human skin melanoma cell line G361. BIOORGANIC CHEMISTRY. 2022.
Jansa J., Jorda R., Škerlová J., Peřina M., Řezníčková E., Heger T., Gucký T., Kryštof V. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2021.
Jorda R., Molitorová V., Vojáčková V., Řezníčková E., Kryštof V. Pseudopeptides with aldehyde or vinylsulfone warheads: Synthesis and antiproteasomal activity. BIOORGANIC CHEMISTRY. 2021.
Razmienė B., Řezníčková E., Dambrauskienė V., Ostruszka R., Kubala M., Žukauskaite A., Kryštof V. Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2H-pyrazolo[4,3-c]pyridines. MOLECULES. 2021.
Dayal N., Řezníčková E., Hernandez DE., Peřina M., Vojáčková V., Kryštof V., Jorda R. 3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo. JOURNAL OF MEDICINAL CHEMISTRY. 2021.
Řezníčková E., Gucký T., Kováčová V., Ajani H., Jorda R., Kryštof V. Activity of 2,6,9-trisubstituted purines as potent PDGFR alpha kinase inhibitors with antileukaemic activity. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2019.
Jorda R., Řezníčková E., Kielczewska U., Bazgier V., Berka K., Rárová L. Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2019.
Jorda R., Lopes SMM., Řezníčková E. Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2019.
Gucký T., Řezníčková E., Radošová Muchová T., Jorda R., Klejová Z., Malínková V., Berka K., Bazgier V., Ajani HB., Lepšík M., Divoký V., Kryštof V. Discovery of N-2-(4-Amino-cyclohexyl)-9-cyclopentyl-N-6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations. JOURNAL OF MEDICINAL CHEMISTRY. 2018.
Jorda R., Hendrychová D., Voller J., Řezníčková E., Gucký T., Kryštof V. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? JOURNAL OF MEDICINAL CHEMISTRY. 2018.
Jorda R., Bučková Z., Řezníčková E., Bouchal J., Kryštof V. Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81. Biochimica et Biophysica Acta - Molecular Cell Research. 2018.
Milisiunaite V., Arbaciauskiene E., Řezníčková E., Jorda R., Malínková V., Žukauskaite A., Holzer W., Sackus A., Kryštof V. Synthesis and anti-mitotic activity of 2,4-or 2,6-disubstituted- and 2,4,6-trisubstituted-2H-pyrazolo[4,3-c]pyridines. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2018.
Řezníčková E., Tenora L., Pospíšilová P., Galeta J., Jorda R., Berka K., Majer P., Potáček M., Kryštof V. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles. European Journal of Medicinal Chemistry. 2017.
Jorda R., Lopes SMM., Řezníčková E., Kryštof V., Pinho e. Melo TMVD. Biological Evaluation of Dipyrromethanes in Cancer Cell Lines: Antiproliferative and Pro-apoptotic Properties. ChemMedChem. 2017.
Xavier NM., Porcheron A., Batista D., Jorda R., Řezníčková E., Kryštof V., Oliveira CM. Exploitation of new structurally diverse D-glucuronamide-containing N-glycosyl compounds: synthesis and anticancer potential. Organic & Biomolecular Chemistry. 2017.
Cavallaro V., Řezníčková E., Jorda R., Alza NP., Murray AP., Kryštof V. Semisynthetic Esters of 17-Hydroxycativic Acid with in Vitro Cytotoxic Activity against Leukemia Cell Lines. Biological and Pharmaceutical Bulletin. 2017.
Dušek J., Imramovský A., Pauk K., Jorda R., Řezníčková E., Kryštof V. Synthesis and Antiproliferative Activities of Novel O-Benzyl Salicylamide Derivatives. Letters in Drug Design and Discovery. 2017.
Xavier NM., Goncalves-Pereira R., Jorda R., Řezníčková E., Kryštof V., Oliveira CM. Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives. Pure and Applied Chemistry. 2017.
Jorda R., Dušek J., Řezníčková E., Pauk K., Magar PP., Imramovský A., Kryštof V. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine. European Journal of Medicinal Chemistry. 2017.
Malínková V., Řezníčková E., Jorda R., Gucký T., Kryštof V. Trisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1. Bioorganic & Medicinal Chemistry. 2017.
Tenora L., Galeta J., Řezníčková E., Kryštof V., Potáček M. Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase. Journal of Organic Chemistry. 2016.
Řezníčková E., Weitensteiner S., Havlíček L., Jorda R., Gucký T., Berka K., Bazgier V., Zahler S., Kryštof V., Strnad M. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro. Chemical Biology and Drug Design. 2015.
Řezníčková E., Popa A., Gucký T., Zatloukal M., Havlíček L., Bazgier V., Berka K., Jorda R., Popa I., Nasereddin A., Jaffe CL., Kryštof V., Strnad M. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. Bioorganic & Medicinal Chemistry Letters. 2015.
Gucký T., Jorda R., Zatloukal M., Bazgier V., Berka K., Řezníčková E., Béres T., Strnad M., Kryštof V. A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry. 2013.
Haider C., Grubinger M., Řezníčková E., Weiss T., Rotheneder H., Miklos W., Berger W., Jorda R., Zatloukal M., Gucký T., Strnad M., Kryštof V., Mikulits W. Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance. Molecular Cancer Therapeutics. 2013.
Imramovský A., Jorda R., Pauk K., Řezníčková E., Dušek J., Hanušek J., Kryštof V. Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines. European Journal of Medicinal Chemistry. 2013.
Zatloukal M., Jorda R., Gucký T., Řezníčková E., Voller J., Pospíšil T., Malínková V., Adamcová H., Kryštof V., Strnad M. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases. European Journal of Medicinal Chemistry. 2013.
Gucký T., Řezníčková E., Džubák P., Hajdúch M., Kryštof V. Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines. Monatshefte für Chemie. 2010.
PATENT, UŽITNÝ VZOR, PRŮMYSLOVÝ VZOR
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V. 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions. 2021.
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V. 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions. 2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M. 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma. 2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M. 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma. 2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M. 5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů. 2020.
Gucký T., Řezníčková E., Jorda R., Divoký V., Kryštof V., Radošová Muchová T., Strnad M. 2,6-disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky. 2019.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2017.
Strnad M., Mikulits W., Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Strnad M., Mikulits W. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
ABSTRAKT
Kořalková P., Niederlová N., Hradilová I., Gurský J., Chaloupková P., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Targeting of SFK and CAMK Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations. Hematologie 2023. 2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Targeting of tyrosine kinases contributing to KMT2A-r mediated leukemogenesis as a therapeutic approach in mixed-lineage leukemia. Czech Annual Cancer Research Meeting (abstract book). 2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Unique kinase inhibitor targeting specifically MLL/FLT3-mediated signaling for personalized medicine in AML. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2023.
Kořalková P., Niederlová N., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcova D., Belickova M., Kryštof V., Divoký V. Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations. Blood. 2022.
Radošová Muchová T., Řezníčková E., Somíková Z., Gucký T., Strnad M., Kryštof V., Divoký V. A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo. Blood (online). 2016.
Řezníčková E., Jorda R., Kryštof V., Havlíček L., Strnad M. A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects. European Journal of Cancer. Supplement. 2010.
Jorda R., Řezníčková E., Kryštof V., Havlíček L., Strnad M. A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects. European Journal of Cancer. Supplement. 2010.
PŘEDNÁŠKA NEBO POSTER
Štarha P., Řezníčková E., Křikavová R., Milde D., Jewula P., Kryštof V. CO2-responsive NADH oxidation by half-sandwich Ir(III) complexes - a curiosity or a problem for cancer cells? 2023.
PROTOTYP, FUNKČNÍ VZOREK
Gucký T., Řezníčková E., Malínková V., Kryštof V. Soubor purinových inhibitorů FLT3-ITD kinázy. 2018.

Uživatel nepovolil zobrazení dat v Portále UP.

Privacy settings

We use cookies and any other network identifiers on our website that may contain personal data (e.g. about how you browse our website). We and some of the service providers we use have access to or store this data on your device. This data helps us to operate and improve our services. For some purposes, your consent is required to process data collected in this way. You can change or revoke your consent at any time (see the link at the bottom the page).

(Essential cookies enable basic functions and are necessary for the website to function properly.)
(Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.)
(They are designed for promotional purposes, measuring the success of promotional campaigns, etc.)